Adjuvant endocrine therapy: Controversies and perspectives

Textbook of Breast Cancer: A Clinical Guide to Therapy

Volumn , Issue , 2006, Pages 205-223

  Visvanathan, Kala ^a   Davidson, Nancy E ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37949004654     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (65)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365(9472): 1687-717.
2. Eifel P, Axelson JA, Costa J et al, National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93(13): 979-89.
3. Goldhirsch A, Glick JH, Gelber RD et al, Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001; 19(18): 3817-27.
4. Goldhirsch A, Wood WC, Gelber RD et al, Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21(17): 3357-65.
5. Visvanathan K, Davidson NE, Aromatase inhibitors as adjuvant therapy in breast cancer. Oncology (Huntingt) 2003; 17(3): 335-42, 347; discussion 347-50, 354.
6. Clemons M, Goss P, Estrogen and the risk of breast cancer. N Engl J Med 2001; 344(4): 276-85.
7. Osborne CK, Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339(22): 1609-18.
8. Smith IE, Dowsett M, Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348(24): 2431-42.
9. Singh A, Purohit A, Duncan LJ et al, Control of aromatase activity in breast tumours: the role of the immune system. J Steroid Biochem Mol Biol 1997; 61(3-6): 185-92.
10. Thijssen JH, Blankenstein MA, Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989; 25(12): 1953-9.
11. Speirs V, Carder PJ, Lane S et al, Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 2004; 5(3): 174-81.
12. Jordan V, Long-term tamoxifen treatment for breast cancer. Madison, Wisconsin: University of Wisconsin, 1994.
13. Early Breast Cancer Trialists' Collaborative Group, Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319(26): 1681-92.
14. Early Breast Cancer Trialists' Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339(8784): 1-15.
15. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351(9114): 1451-67.
16. Fisher B, Dignam J, Wolmark N et al, Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89(22): 1673-82.
17. Fisher B, Dignam J, Bryant J et al, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93(9): 684-90.
18. Fisher B, Costantino JP, Wickerham DL et al, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18): 1371-88.
19. Stewart HJ, Forrest AP, Everington D et al, Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74(2): 297-9.
20. Tormey DC, Gray R, Falkson HC, Postchemo-therapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996; 88(24): 1828-33.
21. Hutchins L, Green S, Ravdin P et al, CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results. In: Annual San Antonio Breast Cancer symposium 1999: San Antonio, Texas, 1999.
22. Reis SE, Costantino JP, Wickerham DL et al, Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93(1): 16-21.
23. Boeddinghaus IM, Dowsett M, Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 2001; 79(1-5): 85-91.
24. Gale KE, Andersen JW, Tormey DC et al, Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen. Cancer 1994; 73(2): 354-61.
25. Paik S, Shak S, Tang G et al, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
26. Paik S, Shak S, Tang G et al, Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Breast Cancer Res Treat 2004; (Suppl 1): 24(Abst).
27. Buzdar A, Howell A, Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7(9): 2620-35.
28. Lonning PE, Aromatase inhibitors and inactivators in breast cancer. BMJ 2001; 323(7318): 880-1.
29. di Salle E, Ornati G, Giudici D et al, Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992; 43(1-3): 137-43.
30. Goss PE, Strasser K, Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19(3): 881-94.
31. Lien EA, Anker G, Lonning PE et al, Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 1990; 50(18): 5851-7.
32. Dowsett M, Tobias JS, Howell A et al, The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 1999; 79(2): 311-15.
33. Jones AL, Powles TJ, Law M et al, Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 1992; 10(10): 1547-52.
34. Boccardo F, Rubagotti A, Amoroso D et al, Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001; 19(22): 4209-15.
35. Schmid M, Jakesz R, Samonigg H et al, Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group, trial 6. J Clin Oncol 2003; 21(6): 984-90.
36. Baum M, Budzar AU, Cuzick J et al, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359(9324): 2131-9.
37. Osborne CK, Hobbs K, Clark GM, Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45(2): 584-90.
38. Baum M, Buzdar A, Cuzick J et al, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial, efficacy and safety update analyses. Cancer 2003; 98(9): 1802-10.
39. Dowsett M, Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; 82(Suppl 1): 4 (Abst).
40. Howell A, Cuzick J, Baum M et al, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-2.
41. Howell A, Effect of anastrozole on bone mineral density: 2 year results of the 'armidex' (anastro-zole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; 82(Suppl 1): 129 (Abst).
42. Duffy S, Jackson TL, Lansdown M et al, The ATAC adjuvant breast cancer trial in post-menopausal women: baseline endometrial subprotocol data. BJOG 2003; 110(12): 1099-106.
43. Thurliman B, BIG 1-98 Collaborative Group, Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. BIG 1-98: A prospective randomized double blind phase II study. The Breast 2005; 14(Suppl 1): S3 (Abst 54).
44. Jakesz R, Kaufmann M, Gnant M et al, Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 trial. Breast Cancer Res Treat 2004; 88(Suppl 1): Abst 2.
45. Coombes RC, Hall E, Gibson LJ et al, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350(11): 1081-92.
46. Boccardo F, Rubagotti A, Puntoni M et al, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Anastrozole Trial. J Clin Oncol 2005; 23(1): 1-10.
47. Goss PE, Ingle JN, Martino S et al, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349(19): 1793-802.
48. Goss PE, Ingle JN, Martino S et al, Letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: NCIC CTG MA17. JNCI in press.
49. Perez EA, Josse RG, Pritchard KI et al, Effect of letrozole versus placebo on bone mineral density in women completing 5 years (yrs) of adjuvant tamoxifen: NCIC CTG MA-17B. Breast Cancer Res Treat 2004; 88(Suppl 1): S36 (Abst 404).
50. Winer EP, Hudis C, Burstein HJ, American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-29.
51. Lees AW, Giuffre C, Burns PE et al, Oophorectomy versus radiation ablation of ovarian function in patients with metastatic carcinoma of the breast. Surg Gynecol Obstet 1980; 151(6): 721-4.
52. Huirne JA, Lambalk CB, Gonadotropin-releas-ing-hormone-receptor antagonists. Lancet 2001; 358(9295): 1793-803.
53. Beatson GT, On the treatment of inoperable cases of carcinoma of the mamma: suggestions for new methods of treatment. Lancet 1896; 348: 1189-96.
54. Paterson R, Clinical trials in malignant disease: Part II Breast Cancer-Value of radiation of the ovaries. J Fac Radiol 1959; 10: 130-3.
55. Early Breast Cancer Trialists' Collaborative Group, Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996; 348(9036): 1189-96.
56. Early Breast Cancer Trialists' Collaborative Group (Cochrane Review), Ovarian ablation for early breast cancer. Chichester, UK. John Wiley and Sons, 2004.
57. Emens LA, Davidson NE, Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003; 9(1 Pt 2): 486-94S.
58. Kaufmann M, Jonat W, Blamey R et al, Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003; 39(12): 1711-17.
59. Scottish Cancer Trials Breast Group and IRCF, Breast Unit, Guy's Hospital, London, Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma. Lancet 1993; 341: 1293-8.
60. Ejlertsen B, Dombernowsky P, Mouridsen H et al, Comparable effect of ovarian ablation and CMF chemotherapy on premenopausal hormone receptor positive breast cancer patients. Proc Am Soc Clin Oncol 1999; 18: 66a.
61. Castiglione-Gertsch M, O'Neill A, Price KN et al, Adjuvant chemotherapy followed by Goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95(24): 1833-46.
62. Davidson NE, O'Neill A, Vukov A et al, Chemohormonal therapy in premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proc ASCO 1999; 18: 67a.
63. Rutqvist L, Zoladex and Tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Research campaign (CRC) Breast Cancer Trials Group, the SouthEast Sweden Breast Cancer Group, Stockholm Breast Cancer Study Group, and the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (GIVIO). Proc Am Soc Clin Oncol 1999; 18: 67a.
64. Jakesz R, Hausmaninger H, Kubista E et al, Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrex-ate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in pre-menopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002; 20(24): 4621-7.
65. Love RR, Duc NB, Allred DC et al, Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002; 20(10): 2559-66.